“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.
Determining whether a company’s quality justifies its price causes headaches for nearly all investors, which is why we started StockStory - to help you separate the real opportunities from the speculative ones. Keeping that in mind, here is one high-flying stock to hold for the long term and two facing an uphill battle.
Two High-Flying Stocks to Sell:
Moog (MOG.A)
Forward P/E Ratio: 42.7x
Responsible for the flight control actuation system integrated in the B-2 stealth bomber, Moog (NYSE: MOG.A) provides precision motion control solutions used in aerospace and defense applications
Why Are We Wary of MOG.A?
- Muted 4.9% annual revenue growth over the last five years shows its demand lagged behind its industrials peers
- Free cash flow margin shrank by 6.6 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive
- Below-average returns on capital indicate management struggled to find compelling investment opportunities
Moog is trading at $403.45 per share, or 42.7x forward P/E. Check out our free in-depth research report to learn more about why MOG.A doesn’t pass our bar.
West Pharmaceutical Services (WST)
Forward P/E Ratio: 38.6x
Founded in 1923 and serving as a critical link in the pharmaceutical supply chain, West Pharmaceutical Services (NYSE: WST) manufactures specialized packaging, containment systems, and delivery devices for injectable drugs and healthcare products.
Why Does WST Worry Us?
- Sales trends were unexciting over the last two years as its 4.9% annual growth was below the typical healthcare company
- Costs have risen faster than its revenue over the last five years, causing its adjusted operating margin to decline by 5.8 percentage points
- Waning returns on capital imply its previous profit engines are losing steam
At $341.42 per share, West Pharmaceutical Services trades at 38.6x forward P/E. Read our free research report to see why you should think twice about including WST in your portfolio.
One High-Flying Stock to Watch:
Kratos (KTOS)
Forward P/E Ratio: 64.5x
Established with a commitment to supporting national security, Kratos (NASDAQ: KTOS) is a provider of advanced engineering, technology, and security solutions tailored for critical national security applications.
Why Does KTOS Catch Our Eye?
- Average organic revenue growth of 14.6% over the past two years demonstrates its ability to expand independently without relying on acquisitions
- Exciting sales outlook for the upcoming 12 months calls for 29.9% growth, an acceleration from its two-year trend
- Earnings growth has massively outpaced its peers over the last two years as its EPS has compounded at 15.8% annually
Kratos’s stock price of $48.37 implies a valuation ratio of 64.5x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
